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Introduction
Breast cancer is a heterogeneous and complex disease 
that encompasses diﬀ   erent entities with distinct bio-
logical features and clinical outcomes [1-3]. Adjuvant 
systemic therapies are employed to eradicate potential 
micrometastatic disease after surgery for early-stage 
cancers but their management remains challenging in 
clinical practice. Treatment decisions still are based largely 
on clinicopathological criteria, including age, tumor size, 
histological grade, lymph node metastasis, lympho-
vascular invasion, and estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) status. Th  ese parameters have 
been incorporated into guidelines such as those of St. 
Gallen [4] and the National Institutes of Health consensus 
or integrated in internet-based decision tools (like 
Adjuvant! Online [5,6]) to aid clinicians evaluating the 
risk of distant recurrence and the need for adjuvant 
chemo  therapy (Figure  1). While this approach has 
improved survival for the average population, it has 
progressively widened the indications of adjuvant 
chemotherapy [7]. Currently, approximately 60% of all 
patients with early breast cancer receive some form of 
chemotherapy; although all patients will be exposed to 
the toxicity of these agents, only a minority will beneﬁ  t 
from it [7,8]. Reliable prognostic and predictive markers 
are needed to guide the selection of the most appropriate 
adjuvant therapies for individual patients with breast 
cancer. In fact, a shift from deﬁ  ning the cancer patients 
who should receive chemotherapy on the basis of their 
prognostic characteristics to deﬁ  ning the patients who 
are likely to beneﬁ  t most from this modality of adjuvant 
treatment is currently taking place.
In the past decade, the development of gene expres  sion 
proﬁ   ling using high-throughput microarray-based 
methods has allowed the concurrent analysis of the 
expres  sion level for thousands of genes in a tumor 
sample. Th   ese technologies were hailed as a new dawn in 
cancer biology and oncology practice; however, after the 
initial wave of enthusiasm, a wave of (over)skepticism 
followed [9,10]. Fortunately, with the signiﬁ  cant number 
of studies based on gene expression proﬁ  ling in the last 
decade and the availability of datasets for reanalyses and 
meta-analyses, the ﬁ  eld of gene expression proﬁ  ling has 
matured.
Microarray-based gene expression proﬁ  ling  studies 
undoubtedly have contributed to our understanding of 
the heterogeneity and complexity of breast cancer 
behavior. It was through a series of seminal studies by the 
Stanford group [11-13] that the breast cancer research 
community has come to terms with the idea that breast 
cancer is by no means a single disease and that distinct 
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features, do exist [11]. Moreover, numerous multigene 
signatures associated with prognosis and response to 
systemic therapies have emerged [1-3]. Some of these 
signatures are commercially available (Table 1) and two 
of them (MammaPrint, Agendia BV, Amsterdam, Th  e 
Netherlands, and Oncotype DX, Genomic Health, 
Redwood City, CA, USA) are currently being tested in 
randomized pros  pective clinical trials [14,15]. Here, we 
discuss the potential clinical relevance of gene proﬁ  ling 
in breast cancer and its potential impact on patients’ 
clinical care.
Molecular classifi  cation of breast cancer
Th  at breast cancer comprises a heterogeneous and 
complex group of tumors has been known for decades, 
and attempts to develop standardized classiﬁ  cation 
systems to account for the diversity of this disease were 
initiated in the late ’60s [16]. Nevertheless, clinical and 
translational investigators had historically considered 
breast cancer to be a single group of tumors in the 
context of clinical trials. Th   e observation that tumors that 
had similar histopathological characteristics behaved in 
distinct manners was often used to disregard the histo-
logical heterogeneity of breast cancer.
Th   e whole landscape of breast cancer research changed 
with the publication of seminal, class discovery, 
microarray-based gene expression proﬁ  ling  studies 
[11-13], in which the heterogeneity and complexity of 
breast cancers were rediscovered at the molecular level 
(Figure 2). To the average ‘microarrayer’ and bioinfor  ma-
tician, the experiments performed by Perou and colleagues 
[11] may now sound almost quaint, but in 2000 they had a 
major impact on how breast cancer was perceived given 
that they demonstrated that (a) ER-positive and ER-
negative breast cancers were funda  mentally distinct at the 
transcriptomic level and (b) breast cancer could be divided 
into at least ﬁ  ve molecular subtypes: luminal A, luminal B, 
normal breast-like, HER2, and basal-like [12,17] (Figure 2).
Several groups have now demonstrated that ER-
positive and ER-negative breast cancers have their prog-
nosis governed by distinct biological processes [18,19] 
Figure 1. Clinical decision-making for adjuvant chemotherapy. Criteria included in the St. Gallen guidelines (green font) and in Adjuvant! 
Online (underlined) are shown. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; uPA/PAI-1, 
urokinase-type plasminogen activator and plasminogen activator inhibitor-1.
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basal-like) have distinct risk factors, clinical presentation, 
histological features, response to therapy, and outcome 
[2,3,20]. Th   ese data have led some experts in the ﬁ  eld to 
suggest that traditional clinicopathological features and 
immunohistochemical markers be replaced by this 
molecular taxonomy [21].
Th   e initial approach employed for the identiﬁ  cation of 
the molecular subtypes was based on hierarchical 
clustering analysis. It should be noted, however, that this 
approach requires large datasets, is to some extent 
subjective, and cannot be employed for the classiﬁ  cation 
of individual samples prospectively [22-25]. Th  erefore, 
‘single sample predictors’ (SSPs) were developed on the 
basis of the correlation between the expression proﬁ  le of 
a given sample with the centroids for each molecular sub-
type (that is, average expression proﬁ  le of each molecular 
subtype) [13,17,26]. Over the last decade, three distinct 
SSPs were developed [13,17,26]. Further  more, on the 
basis of this approach, Parker and colleagues [17] developed 
a quantitative reverse transcriptase-poly  merase chain 
reaction (qRT-PCR)-based or NanoString-based method 
(PAM50) that can be used to classify formalin-ﬁ  xed 
paraﬃ     n-embedded (FFPE) samples into the molecular 
subtypes. Our group [27] and others [28,29] have 
demonstrated that subtle variations in data normalization 
and centering, as well as in the proportion of samples 
from each of the subtypes, may lead to changes in the 
classi ﬁ  cation of samples using SSPs. Moreover, indepen-
dent groups have demonstrated that the classiﬁ  cation of 
tumors into the molecular subtypes, except for the basal-
like subtype, is dependent on the SSP used [27,28]. Th  is  is 
best exempliﬁ   ed by the modest agreement in the 
classiﬁ  cation of samples (agreement of 64%, kappa score 
of 0.527, and 95% conﬁ  dence interval of 0.456 to 0.597) 
when a cohort of 295 breast cancers was classiﬁ  ed into 
the molecular subtypes by the authors of the original 
studies on the molecular classiﬁ   cation using SSPs by 
Sorlie’s [13,30] and Perou’s [26,31] groups.
Despite the enthusiasm for the use of this molecular 
taxonomy for the design of clinical trials and routine 
oncology practice, there are several issues that ought to 
be considered. First, the subdivision of luminal tumors 
into A and B is strongly dependent on the SSP used [27] 
and principally depends on the expression of prolifera  tion-
related genes [17,26,32]; there is burgeoning evidence to 
Figure 2. Schematic illustrations of the fi  ve major clusters that represent the molecular subtypes of breast cancer. Perou and colleagues 
[11] carried out a cDNA microarray analysis of 38 invasive breast cancers, 1 ductal carcinoma in situ, 1 fi  broadenoma and 3 normal breast samples, 
and a number of biological replicates of tumors from the same patients and defi  ned an ‘intrinsic gene’ list (that is, genes that vary more between 
tumors from diff  erent patients compared with samples from the same tumor/patient). Hierarchical clustering analysis using these ‘intrinsic’ 
genes led to the identifi  cation of four subtypes: luminal, normal breast-like, human epidermal growth factor receptor 2 (HER2), and basal-like. In 
subsequent studies, it was demonstrated that similar molecular subtypes of breast cancer could be identifi  ed in multiple cohorts and that luminal 
cancers could be subclassifi  ed into two groups (luminal A and B) [12] or three groups (luminal A, B, and C) [13]. The estrogen receptor (ER)-positive 
branch of the dendrogram contains the luminal tumors, which express low-molecular weight cytokeratins 8/18, ER, and genes associated with an 
active ER pathway [2,3,11-13,17,26,34]. Luminal A tumors (dark blue) present high levels of expression of ER-activated genes and low proliferation 
rates and are associated with an excellent prognosis, whereas luminal B breast cancers (light blue) are more often of higher histological grade 
and have higher proliferation rates and a worse prognosis [2,3,11-13,17,26,34]. The ER-negative branch includes at least three subtypes: normal 
breast-like, HER2, and basal-like. HER2 tumors (purple) overexpress HER2 and genes associated with the HER2 amplicon on 17q12 (that is, GRB7) 
and/or the HER2 pathway [2,3,11-13,17,26,34]. Basal-like tumors (red) express genes usually found in normal basal/myoepithelial cells of the 
breast, including high-molecular weight cytokeratins (5 and 17), caveolins 1 and 2, P-cadherin, nestin, CD44, and EGFR [20]. Morphological and 
immunohistochemical features of basal-like cancers are similar to those described for tumors arising in BRCA1 germ-line mutation carriers [20]. 
The HER2 and basal-like subgroups share an aggressive clinical behavior. Normal breast-like cancers (green) are still poorly characterized [3,22] and 
there is evidence to suggest that they may constitute an artefact of gene expression profi  ling associated with a disproportionately high content of 
normal breast tissue [3,17,26,34].
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genes in luminal cancers forms a continuum [3,19,33] 
and that the division of these tumors into two subgroups 
on the basis of the currently available SSPs [13,17,26] may 
be artiﬁ  cial. Th  e subclassiﬁ  cation of ER-positive breast 
cancers into subtypes is not only a challenge for the 
‘intrinsic’ subtype classiﬁ  cation. In fact, given that proli-
fera  tion is a continuum in ER-positive cancers and that 
proliferation is a strong determinant of outcome in this 
group of tumors, the allocation of ER-positive breast 
cancer patients into good or poor prognosis by using other 
microarray-based methods (for example, MammaPrint 
and genomic grade index) or into low, intermediate, or 
high histological grade should be considered arbitrary to 
some extent (see ‘Multigene prognostic signa  tures’ 
section). Second, normal breast-like cancers are now 
considered by some to be an invalid molecular subtype 
given that these tumors are likely to constitute an artefact 
of frozen tissue procurement and representation (that is, 
samples with a disproportionately high content of normal 
breast and stromal cells) [3,17,26,27,34,35]. Th  ird, the 
HER2 (or HER2-enriched) subtype as deﬁ  ned by micro-
arrays does not encompass all cases classiﬁ  ed as HER2-
positive by clinically validated methods (that is, immuno-
histochemistry and in situ hybridization with methods 
approved by the US Food and Drug Adminis  tration), and 
not all HER2-positive cancers by clinical methods are 
classi ﬁed as HER2 subtype by microarrays [3,17,21,36,37].
Th   e above discrepancies do not invalidate the existence 
of the ‘intrinsic’ subtypes. As recently pointed out by 
Perou and colleagues [38], this is an evolving classiﬁ  cation 
system and PAM50 [17], rather than the SSPs described 
by Sorlie and colleagues [13] or Hu and colleagues [26], 
should be employed. With the development of the 
PAM50 assay, prospective testing of this classiﬁ  cation by 
independent groups will determine its prognostic and 
predictive power and clinical utility above and beyond 
the clinicopathological parameters currently available.
Th   e putative histogenetic implications of the molecular 
subtypes (that is, luminal cancers would originate from 
luminal cells and basal-like cancers would stem from basal/
progenitor cells) [12,13,39-42] have proven incorrect. 
Although this observation does not have a direct impact 
on the clinical utility of the ‘intrinsic’ molecular subtypes, 
it has led to the assumption that diﬀ  erent subtypes of 
breast cancer would originate from diﬀ  erent cell types 
[13,39-42]. Importantly, there is independent direct 
evidence to demonstrate that the likeliest cell of origin of 
basal-like breast cancers lies in the luminal progenitor 
population rather than the ‘basal’ population of the 
normal breast [43,44].
Additional evidence to support the contention that the 
‘intrinsic’ molecular taxonomy remains a working model 
in development stems from the recent identiﬁ  cation of at 
least three additional molecular subtypes of ER-negative 
cancers: the ‘interferon-rich’ subtype [26,45], the ‘mole-
cu  lar apocrine’ subtype [46-48], and the ‘claudin-low’ 
subgroup [35,49] (Figure 2). Th   e ‘interferon-rich’ subtype, 
ﬁ  rst described by Hu and colleagues [26], is characterized 
by high expression of interferon-regulated genes, such as 
STAT1 [26,45]; the ‘molecular apocrine’ subtype, which is 
characterized by activation of androgen receptor signal-
ing, frequently displays HER2 gene ampliﬁ  cation and may 
be associated with PTEN germline mutations [46-48]; 
and the ‘claudin-low’ subgroup, which comprises tumors 
that express low levels or lack of expression of E-cadherin 
and claudin mRNA, displays an enrichment for the 
expres  sion of genes often expressed in the process of 
epithelial-to-mesenchymal transition and immune res-
ponse genes and allegedly harbors features suggestive of a 
‘cancer stem cell-like’ phenotype [35,49]. Intriguingly, 
greater than 40% of these cancers do express E-cadherin 
and claudins at the protein level, despite the low 
expression levels of these genes by microarray analysis 
[35]. Importantly, a substantial proportion of tumors 
classiﬁ  ed as of claudin-low subtype by using the cell line-
derived SSP described by Prat and colleagues [35] were 
previously classiﬁ  ed as normal breast-like by using other 
SSPs; these samples may have a disproportionately high 
content of stromal and normal breast cells. Hence, it 
remains to be determined whether breast cancers that do 
express E-cadherin and claudins at the protein level and 
that were classiﬁ  ed as claudin-low by the SSP predictor 
were not classiﬁ   ed as such due to stromal cell 
contamination. Another point for considera  tion is the 
overlap between the transcriptomic charac  teristics of the 
claudin-low subtype and those of spindle cell metaplastic 
breast carcinomas [49,50].
Given the above observations, but despite recent claims 
that PAM50 models derived from archival formalin-ﬁ  xed 
RNA are ‘a potential replacement for grade-, hormone 
receptor-, Ki67-, and HER2-based prognostic models’ 
[21], we argue that the microarray-based gene classiﬁ  -
cation for breast cancer is not yet ready for clinical use in 
prognostic models or otherwise [1,3,8,27]. In fact, stan-
dardi  zation of the deﬁ  nitions and the methodologies for 
the identiﬁ  cation of the molecular subtypes and pros  pec-
tive clinical trials to validate the contribution of the 
‘intrinsic’ subtypes in addition to the current clinico-
pathological parameters for the management of breast 
cancer patients are still required [1,3,8,27]. Robust, 
independently validated methods for the identiﬁ  cation of 
these subtypes are yet to be published.
Multigene prognostic signatures
First-generation signatures
Th  e development of microarray-based multigene prog-
nostic classiﬁ   ers (also known as ‘gene signatures’) has 
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with the aim of deﬁ  ning which patients would have such 
a good prognosis that they could forgo chemotherapy. 
Th  e ﬁ  rst prognostic gene signature [51] consisted of 70 
genes and was shown to identify a group of good-
prognosis patients with minimal risk of development of 
distant metastasis within 5 years in patients who were 
systemic therapy-naïve. In a subsequent study, van de 
Vijver and colleagues [59] demonstrated that the 70-gene 
signature was a predictor of outcome independently of 
the current clinicopathological prognostic markers in a 
dataset comprising 295 cases (64 cases from the analysis 
that led to the development of the 70-gene signature and 
231 new cases). Importantly, in that [59] and subsequent 
[60,61] studies, it has been repeatedly demonstrated that 
the 70-gene signature classiﬁ  es greater than 95% of ER-
negative cancers as poor prognosis and that there is a 
strong correlation between 70-gene signature-deﬁ  ned 
poor prognosis and high histological grade. Furthermore, 
the studies demonstrated that the 70-gene signature 
would outperform the current methods based on clinico-
pathological parameters for chemotherapy use [51,59]. 
Th  is has led to the development of MammaPrint, a 
commercially available version of the 70-gene signature. 
Subsequent studies have led to the development of 
several other prognostic signatures, including the 76-gene 
signature [54,62] and genomic grade index [55,63-65], 
which were also shown to be independent predictors of 
outcome. MammaPrint is currently being tested in the 
MINDACT (Microarray In Node-negative and 1-3 
positive lymph-node Disease may Avoid ChemoTh  erapy) 
trial [15] (Figure 3), which will deter  mine whether this 
signature can actually replace clinico  pathological para-
meters for the identiﬁ  cation of patients who could be 
spared from the use of chemotherapy. Table 1 summar-
izes the prognostic signatures more extensively studied to 
date. For comprehensive reviews on microarray-based 
prognostic gene signatures, readers are referred to 
Sotiriou and Pusztai [2], Weigelt and colleagues [3], and 
Kim and Paik [66].
In parallel with the development of microarray-based 
prognostic signatures, Paik and colleagues [52] developed 
Oncotype DX, a qRT-PCR-based analysis of 21 genes (16 
cancer-related and 5 reference genes), which can be used 
for risk stratiﬁ  cation of ER-positive, node-negative breast 
cancers from patients treated with adjuvant tamoxifen. In 
contrast to microarray-based predictors, Oncotype DX 
can be applied to FFPE samples, and this test was 
developed and validated on the basis of a retrospective 
analysis of the existing material from two randomized 
clinical trials (NSABP-B-20 and NSABP-B-14). Th  e 
signature is based on the expression of genes that are 
associated with proliferation, ER signaling, HER2, and 
invasion [52]. Th   e expression of these genes is presented 
as a recurrence score (RS) that ranges from 0 to 100. 
Th  ese scores provide an estimate of 10-year distant 
recurrence risk. For clinical use, patients are separated 
into three categories: low-risk (RS <18), inter  mediate-
risk (RS ≥18 and <31), and high-risk (RS ≥31) [52]. 
Oncotype DX has been shown to be an independent 
prognostic factor for patients with ER-positive, node-
negative breast cancers treated with tamoxifen and to 
outperform standard clinicopathological parameters for 
the prediction of 10-year distant recurrence risk [52]. 
Oncotype DX has been subsequently evaluated in other 
populations of breast cancer [67] and shown to be an 
independent prognostic parameter in patients with ER-
positive tumors with up to three positive nodes receiving 
adjuvant chemotherapy [68] and in postmenopausal 
patients with ER-positive tumors treated with aromatase 
inhibitors (that is, anastrozole) [69].
Oncotype DX RSs have also been shown to be corre  lated 
with the beneﬁ   t patients derive from adjuvant chemo-
therapy in samples from clinical trials [70-72]. In fact, 
patients with tumors displaying high RSs despite the poor 
prognosis derive signiﬁ  cantly more beneﬁ  t from chemo-
therapy than those with low-RS tumors. In addition, 
patients with low-RS cancers appear to derive negligible 
beneﬁ  t from the addition of chemotherapy to tamoxifen 
[70,71]. Th   erefore, Oncotype DX has also been considered 
a predictive marker of beneﬁ  t from chemotherapy.
Despite the numerous publications on ﬁ  rst-generation 
signatures, level II evidence to support the prognostic 
role was achieved only for Oncotype DX; for the 
remaining signatures, only level III evidence has been 
obtained so far. Given the level of evidence that has been 
accrued, Oncotype DX has received approval from the 
American Society of Clinical Oncology [73] and was 
included in the National Comprehensive Cancer Network 
guidelines (Breast Cancer version 1.2011 [74]) as an 
option to evaluate prognosis and as a complement to 
clinicopathological features to predict response to 
chemotherapy for patients with ER-positive, node-
negative breast cancer. None of the microarray-based 
prognostic signatures has been endorsed by these 
professional bodies.
Are the fi  rst-generation prognostic gene signatures ready 
for use in clinical practice?
Although the diﬀ  erent  ﬁ   rst-generation signatures des-
cribed above provide relevant information for outcome 
prediction, they have yet to be incorporated into clinical 
practice [1,3,8]. Th  e reasons for this apparent failure are 
multifactorial, and not a single ﬁ  rst-generation signature is 
currently supported by level I evidence for their prognostic 
power. Th  is information will be available only after the 
completion of the two randomized trials, MINDACT [15] 
and TAILORx (Trial Assigning IndividuaLized Options 
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the genomic signatures MammaPrint and Oncotype DX, 
respectively.
First-generation signatures have been shown not to be 
stable in terms of the list of genes they are composed of 
[75,76]; however, comparative studies and meta-analyses 
have demonstrated that, despite having a negligible over-
lap in their constituent genes, the ﬁ  rst-generation signa-
tures tend to have similar performance and show a 
relatively good concordance in their prognostic classiﬁ  -
cation, identifying similar but not identical subgroups of 
patients with poor prognosis [31,33,77].
Th   e ability of these signatures to determine prognosis 
seems to be directly correlated to the assessment of 
proliferation-/cell cycle-related genes [18,33]. Th  e fact 
that these ﬁ  rst-generation signatures arguably are mere 
surrogates of proliferation poses some important 
problems for their use. First, given that proliferation has 
been shown to be prognostic in ER-positive disease and 
not in ER-negative cancers, ﬁ  rst-generation  signatures 
are applicable only for the prognostication of patients 
with ER-positive and HER2-negative breast cancers 
[18,54,  60,61]. As the expression level of proliferation-
related genes in ER-positive cancers has been demon-
strated to follow a continuum rather than a bimodal 
distribution, the subdivision of ER-positive cancers into 
good-prognosis (that is, luminal A) and poor-prognosis 
(that is, luminal B) groups is artiﬁ  cial [18,33]. In fact, the 
continuous nature of the Oncotype DX RS is more 
representative of the ranges of prognosis of patients with 
ER-positive disease. It should be noted, however, that this 
approach for clinical decision-making may be proble-
matic. For instance, the prognostication and management 
of patients with an intermediate RS remain unclear, and 
Figure 3. MINDACT (Microarray In Node-negative and 1-3 positive lymph-node Disease may Avoid ChemoTherapy) randomized 
trial design. The clinical impact of MammaPrint is being evaluated in MINDACT, a prospective multicenter randomized trial conducted by the 
European Organization for Research and Treatment of Cancer. The trial compares the recurrence-risk assessment of the 70-gene signature with 
that provided by Adjuvant! Online in selecting patients for adjuvant chemotherapy. Patients with concordant results are being treated accordingly 
(high-risk: chemotherapy with or without endocrine therapy, depending on estrogen receptor (ER) status; low-risk: hormonal therapy if ER-positive 
without chemotherapy). Discordant cases are being randomly assigned to receive adjuvant therapy on the basis of either clinicopathological or 
70-gene signature risk assessment. Launched in 2006, the trial intends to confi  rm the validity of the signature and demonstrate that its clinical 
use would reduce the number of patients receiving unnecessary treatments, but the results will probably take years to be revealed. Clinico-path, 
clinicopathological; N, lymph node; N0, lymph node-negative; RANDOM, randomization; TAM, tamoxifen; yrs, years.
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(that is, breast cancers combining ER-positive, HER2-
negative, and grade II status) are allocated to the 
intermediate-risk RS group [78]. Th  erefore, the actual 
contribution of Oncotype DX to the management of this 
particular group of patients remains to be elucidated 
[78]. Th  e lack of prognostic power of ﬁ  rst-generation 
prognostic signatures in ER-negative breast cancer and 
their association with proliferation in ER-positive breast 
cancer have brought to the forefront of cancer research 
the limitations of histological grading. In a way akin to 
ﬁ  rst-generation prognostic gene signatures, histological 
grade is not prognostic in ER-negative disease and is 
strongly associated with proliferation [18,79]. It should 
be noted, however, that the levels of intra- and inter-
observer agreement of histological grade remain sub-
optimal, despite the numerous eﬀ  orts to implement a 
standardized histological grading system [79]. It could be 
argued, on the basis of the above obser  vations, that the 
major contribution of ﬁ   rst-generation prognostic gene 
signatures is to provide a standardized proliferation assay 
for breast cancer.
A second limitation of the ﬁ  rst-generation prognostic 
signatures stems from the fact that most of them were 
developed to predict short-term distant recurrence 
(<5  years) and were shown to have a strong ‘time 
dependence’ and a reduced prognostic value after 5 to 
10  years of follow-up [61,80]. Hence, these signatures 
may represent merely early distant recurrence surrogates 
and are unable to predict late relapses with the same 
accuracy. Th   us, there is still a need to develop signatures 
that could identify patients who have a higher risk of late 
relapse and who may beneﬁ  t from prolonged therapy.
Another important consideration in relation to the 
currently available ﬁ  rst-generation prognostic signatures 
is that they were derived on the basis of the analysis of 
tissue samples with varying contents of neoplastic cells, 
stromal cells, inﬂ  ammatory inﬁ  ltrate, and normal breast 
tissue. Th   ere is evidence to suggest that the percentage of 
non-neoplastic cells has a substantial impact on the ﬁ  nal 
expression proﬁ  le of a tumor and on the ability to derive 
biologically meaningful prognostic signatures [81]. It 
should be noted that, although stromal cells and inﬂ  am-
matory inﬁ  ltrate may be integral parts of the expression 
proﬁ  le of a tumor and provide important prognostic and 
predictive information, most studies employed samples 
with percentages of stromal cells, inﬂ  ammatory inﬁ  ltrate, 
and normal breast tissue ranging from 0% to 50%. 
Table 1. Prognostic multigene signatures in breast cancer commercially available or in commercial development
  MammaPrint  Oncotype DX  Theros/MGI  MapQuant DX/  Veridex 76-gene
Signature [51,59]  [52]  [53,56-58]  simplifi  ed [55]  [54]
Commercially 
available/Provider
Yes/Agendia BV 
(Amsterdam, The 
Netherlands)
Yes/Genomic Health 
(Redwood City, CA, USA)
Yes/ bioTheranostics, Inc. 
(San Diego, CA, USA)
Yes/Ipsogen Inc. 
(Stamford, CT, USA)
No/Johnson & Johnson 
(New Brunswick, NJ, 
USA)
Study population ER+ and ER−, N0, <5 cm 
diameter, age <55 years
ER+, N0, TAM treated ER+, N0 ER+ and ER−, N0 and N+ ER+ and ER−
Assay 70-gene signature 21-gene Recurrence 
Score
2-gene HOXB13:IL17R/
molecular-grade index
97-gene signature/8-gene 
PCR
76-gene signature
Platform Microarray (Agilent 
Technologies, Inc., Santa 
Clara, CA, USA)
RT-PCR RT-PCR Microarray (Aff  ymetrix, 
Santa Clara, CA, USA)/
RT-PCR
Microarray (Aff  ymetrix)
Tissue type Frozen or stabilized mRNA FFPE FFPE Frozen/FFPE Frozen
Prognostic value in 
other populations
Age 55-70 years, 1-3 N+, 
N0 and N+, HER2+
ER+ and 1-3 N+, ER+ 
postmenopausal 
receiving aromatase 
inhibitors
- ER+ receiving aromatase 
inhibitors
Predictive value Neoadjuvant and 
adjuvant CT (poor 
signature)
Neoadjuvant and 
adjuvant CT [71] 
(high-RS), response to 
TAM (low-RS)
Resistance to TAM 
(high-ratio)
Response to neoadjuvant 
CT (high-risk)
Response to TAM 
(high-risk patients)
Indication Prognostic in N0, <5 cm 
diameter, stage I/II BC, 
age <61 years
Prediction of recurrence 
risk in ER+ and N0 BC 
treated with TAM
Prognostic in ER+ BC, 
prediction of response 
to TAM
Molecular grading, for 
ER+, histological grade 
II BC
Prognostic in ER+ BC
Level of evidence III II III III III
FDA approval Yes No No No No
Randomized trial MINDACT TAILORx - - -
Availability Europe and USA Europe and USA USA Europe -
BC, breast cancer; CT, chemotherapy; ER; estrogen receptor status (+ or −); FDA, US Food and Drug Administration; FFPE, formalin-fi  xed paraffi   n-embedded; HER2, 
human epidermal growth factor receptor 2; HOXB13, homeobox 13; IL-17BR, interleukin-17B receptor; MGI, molecular grade index; MINDACT, Microarray In Node-
negative and 1-3 positive lymph-node Disease may Avoid ChemoTherapy; N+, lymph node-positive; N0, lymph node-negative; PCR, polymerase chain reaction; RS, 
recurrence score; RT-PCR, reverse transcriptase-polymerase chain reaction; TAILORx, Trial Assigning IndividuaLized Options for Treatment Rx; TAM, tamoxifen.
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the same tumor with drastically diﬀ  erent percentages of 
neoplastic cells (for example, 50% versus 100%) would be 
allocated to the same prognostic subgroup consistently. 
Th  erefore, methods to estimate the non-neoplastic cell 
content of samples or tissue microdissection to standard-
ize the proportion of neoplastic/non-neoplastic cells 
would be desirable in the development of new micro-
array-based classiﬁ  ers and implementation of currently 
available gene expression signatures.
Despite the initial claims that these signatures would 
replace current clinicopathological parameters for the 
management of patients with breast cancer, clinicopatho-
logical variables have been shown to add prognostic infor-
mation independent from that oﬀ  ered by ﬁ  rst-genera  tion 
signatures [1-3]. Th  erefore, these gene signa  tures should 
be perceived as ancillary tools that complement current 
methods based on the clinicopatho  logical features of the 
tumors rather than as a replace  ment for them [1-3]. 
Importantly, the additional prog  nostic information pro-
vided by ﬁ  rst-generation signa  tures appears to be limited 
when clinicopathological parameters are analyzed in a 
centralized fashion with standardized methods (that is, 
centralized reassessment of histological grade and 
standard  ized assessment of ER, PR, HER2, and prolifera-
tion rate as deﬁ  ned by Ki67 immunohisto  chemical analy-
sis) [82]. Th   erefore, the true contribution of the commer-
cially available ﬁ  rst-generation signatures beyond tumor 
morphology and immunohistochemistry remains to be 
determined [8].
Recently, ‘second-generation’ signatures speciﬁ  c for the 
distinct subtypes of breast cancers have been reported by 
studying breast cancer microenvironment or host immune 
response [1,83-87]. Immune response-related signatures 
Figure 4. TAILORx (Trial Assigning IndividuaLized Options for Treatment Rx) randomized trial design. Oncotype DX is being tested in 
TAILORx, a prospective randomized phase III trial coordinated by the Breast Cancer Intergroup. The purposes of this trial are to confi  rm the 
prognostic value of the 21-gene recurrence score (RS), to determine the optimal management of patients with intermediate-RS, and to refi  ne the 
utility of the assay in clinical practice. The accrual was recently completed and the fi  rst results will be disclosed in 2013. Patients with estrogen 
receptor (ER)-positive, node-negative breast cancers were eligible and were separated in three study groups according to their RS. High-RS patients 
(RS >25) received chemotherapy plus endocrine therapy, whereas low-RS patients (RS <11) were assigned to endocrine therapy alone. Patients with 
intermediate-RS (RS = 11 to 25) were randomly assigned to receive either hormonal therapy alone or hormonal therapy plus chemotherapy. To 
minimize potential under-treatment in both the high-risk and the randomly assigned groups, the RS ranges for TAILORx were diff  erent from those 
originally defi  ned (11 to 25 instead of 18 to 31). FFPE, formalin-fi  xed paraffi   n-embedded; N0, lymph node-negative; RANDOM, randomization.
BREAST CANCER n=10,500 
N0 and ER+
FFPE Ɵ FFPE Ɵssues
21-gene Recurrence Score (RS) 21 gene Recurrence Score (RS)
Oncotype DX
Tissue bank
(FFPE)
RS < 11
RSш 11 andч 25
(n=4,390)
RS >25
RANDOM
CHEMOTHERAPY  ENDOCRINE THERAPY
ENDOCRINE THERAPY OC
PRIMARY END POINT: Disease-free survival
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Page 8 of 15have been shown to be potential prog  nosticators in ER-
negative or triple-negative breast cancers [83-85]. Although 
these signatures are promising,  additional evidence in 
support of the use of these signatures as potential 
predictors of outcome is still required.
Multigene predictive signatures
Beyond prognostic classiﬁ  ers, an important challenge is 
to provide physicians with biomarkers that could predict 
the response or lack of response to treatments and 
determine the most eﬀ   ective regimen for a speciﬁ  c 
patient or subgroup of patients. In clinical practice, only 
ER and HER2 are currently used as predictive markers 
for the selection of patients likely to respond to endocrine 
therapy and trastuzumab, respectively.
In addition to Oncotype DX, whose RSs have been 
shown to be associated with beneﬁ  t from the addition of 
chemotherapy to tamoxifen, other prognostic signatures 
were also shown to have predictive value for the incre-
mental beneﬁ  t of chemotherapy [1-3,65,88,89]. However, 
unlike Oncotype DX, the predictive power of MammaPrint 
[88,89] and genomic grade index [65] have only been 
tested in retrospective datasets from patients treated 
with multidrug chemotherapy regimens.
Gene expression signatures and response to chemotherapy
With the clinical need for predictive markers for speciﬁ  c 
chemotherapy agents and multidrug regimens, several 
groups have developed multigene signatures speciﬁ  cally 
designed to predict response in patients receiving either 
chemotherapy or endocrine therapy. Using supervised 
approaches, several studies have attempted to identify 
multigene signatures of response to chemotherapy by 
comparing gene expression proﬁ   les between high-
sensitivity and low-responsiveness tumors [90-93]. Th  e 
majority of the studies focused on neoadjuvant chemo-
therapy and, by means of microarrays or RT-PCR, 
analyzed tumor samples obtained from biopsies taken at 
diagnosis before initiation of chemotherapy (Table 2).   
Chemotherapy sensitivity usually was estimated with rate 
of pathological complete response to neoadjuvant 
therapy (pCR) as a surrogate of long-term beneﬁ  t from 
the treatment. For example, the MD Anderson Cancer 
Center group developed a 30-gene signature in 82 breast 
cancer patients receiving T/FAC chemotherapy (pacli-
taxel, ﬂ   uorouracil, doxorubicin, cyclophosphamide) 
[90,92]. Th   is DLDA-30 predictor was then validated in 51 
independent patients and predicted pCR probability with 
higher sensitivity and negative predictive value than 
clinical variables based on age, grade, and ER status [92]. 
Th  e accuracy of this predictor was conﬁ   rmed in an 
indepen  dent study [94]. Despite these interesting pre-
liminary results, the accuracy of the 30-gene predictor 
was not found in a recent study in which it was not an 
independent predictor of pCR after multivariate analysis 
and did not perform better than clinical variables, 
questioning its potential utility in the clinical setting [95].
An alternative attempt to predict chemosensitivity to 
speciﬁ  c chemotherapy regimens was developed with the 
use of in vitro models [96]. Th   e combination of in vitro 
signatures associated with drug sensitivity in cell lines 
was thought to provide composite signatures that could 
predict response to multidrug regimens and be translated 
to patients receiving multidrug chemotherapy [96]. Th  ese 
‘regimen-speciﬁ  c’ signatures tested in patients who, as 
participants in the European Organization for Research 
and Treatment of Cancer (EORTC) BIG00-01 clinical 
trial, received TET (docetaxel, epirubicin-docetaxel) or 
FEC (ﬂ   uorouracil, epirubicin, and cyclo  phos  phamide) 
chemotherapy resulted in a validation study published in 
2007 [97]. Importantly, problems with the methodology 
of these studies have been identiﬁ  ed [98-100] and serious 
concerns about the validity of the published results were 
raised [101,102]. Subsequently, after a series of investi-
gations, the ﬁ  ndings derived from in vitro studies were 
considered invalid, and this led to the discontinuation of 
the clinical trials based on these prediction models. 
Furthermore, several high-proﬁ   le publi  cations have 
recently been retracted.
Another method to develop multigene classiﬁ  ers  of 
chemosensitivity is based on the use of metagenes (that 
is, groups of coexpressed genes associated with a small 
number of biological processes). A retrospective micro-
array analysis of prospectively collected ER-negative 
breast cancer samples demonstrated that increased 
stromal gene expression predicted resistance to FEC 
chemotherapy [103]. Th  is ‘stromal’ multigene classiﬁ  er 
was subsequently validated in two independent cohorts 
[103]. Further validation of this metagene is awaited.
Despite the promising initial results, the signatures of 
chemotherapy sensitivity have so far had limited use in 
clinical practice. Most of them have been developed in 
small, convenience cohorts and require further external 
validation. None of the diﬀ  erent predictors of chemo-
sensitivity is commercially available, and additional 
evidence is still required before they can be implemented 
in clinical practice. For a detailed discussion of the 
reasons for the limited success of the predictive signa-
tures available to date, readers are referred to a recent 
review by Borst and Wessels [102]. On the basis of the 
design employed in most of the studies, the predictive 
signatures for multidrug regimens are likely to capture 
the transcriptomic features of sensitivity/resistance to 
cytotoxic agents in general. Th   ese mechanisms may con-
stitute convergent phenotypes [104] (that is, there are 
multiple genetic/epigenetic aberrations that may lead to 
resistance to cytoxic agents). Th  e next generation of 
signatures ought to focus on speciﬁ  c drugs within a given 
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chemo  therapy in ER-positive and ER-negative breast 
cancers appear to be fundamentally diﬀ  erent  [19]. 
Furthermore, potential mechanisms of resistance to 
chemotherapy identiﬁ   ed by orthogonal methods (for 
example, RNA inter  ference screens [105], microarray-
based comparative genomic hybridization [106,107], 
proteomic analyses [108], and hypothesis-driven studies 
[109]) may be used as the basis for the development of 
multigene predictive signatures. With the availability of 
multiple microarray datasets from retrospective cohorts 
and clinical trials in the public domain, novel signatures 
derived from analyses using orthogonal methods can be 
tested in a timely fashion.
Predictive multigene markers of response to endocrine 
therapy
ER status has an important negative predictive value for 
evaluating the response to anti-estrogen therapy. Never-
theless, ER expression alone is not suﬃ   cient to predict 
which ER-positive tumor will respond or be resistant to 
diﬀ  erent modalities of endocrine therapies. Microarray-
based gene expression signatures to predict outcome of 
tamoxifen-treated patients have been developed (Table 3). 
For example, a 44-gene signature, identiﬁ  ed by Jansen 
and colleagues [110], compared gene expression proﬁ  les 
in patients with advanced ER-positive breast cancers 
treated by tamoxifen. Other hormone sensitivity tests 
studying estradiol-induced genes in MCF-7 cell line 
culture [111] or clusters of correlated genes [112] have 
also been reported.
More recently, the sensitivity to endocrine therapy 
(SET) index was developed in a large series of ER-positive 
breast cancers [113]. Th  e SET index is based on the 
principle that expression of genes correlated with ER may 
better predict response to endocrine treat  ment than ER 
expression alone [113]. Microarray analysis of a discovery 
set of ER-positive tumors led to the identiﬁ  cation of 165 
genes coexpressed with ER; the SET index was devised 
and applied to a validation cohort to deﬁ  ne  three 
categories of sensitivity (low, intermediate, and high). 
Association between SET and outcome was then 
analyzed in three types of ER-positive cohorts receiving 
either adjuvant tamoxifen for 5 years or neoadjuvant 
chemotherapy followed by endocrine therapy (tamoxifen 
or aromatase inhibition) or no adjuvant sys  temic 
treatment. Th  e SET index was signiﬁ  cantly  asso  ciated 
with the outcome of patients receiving any type of 
endocrine treatment (tamoxifen or chemo  endo  crine 
treatment) but had no prognostic value in untreated 
patients. Unlike other multigene signatures evaluating 
proliferation in ER-positive tumors, the SET index seems 
to be predictive of beneﬁ   t from endocrine therapy 
independently of the inherent prognosis of the tumor. 
Interestingly, for a potential clinical application, the SET 
index could identify a subset of tumors associated with 
an excellent prognosis and no relapse in the tamoxifen-
treated group (node-negative and high-SET index tumors) 
and in the chemoendocrine group (high- and intermediate-
SET index). Studies evaluating the clinical relevance of 
the SET index are warranted to expand its indications in 
clinical practice.
Table 2. Multigene predictors of sensitivity to chemotherapy
 Number      Chemosensitivity         
Authors of  casesa Regimen Chemotherapy  evaluation  Technology  Method Signature NPV  PPV  Accuracy
Chang 
et al. [116]
24 discovery 
6 validation
Neoadjuvant Docetaxel Clinical response cDNA 
microarray
Supervised 92 genes 83% 92% 88%
Ayers 
et al. [90]
24 discovery 
12 validation
Neoadjuvant T/FAC pCR cDNA 
microarray
Supervised 74 genes 73% 100% 
(3/3)
78%
Iwao-
Koizumi 
et al. [91]
44 discovery 
26 validation
Neoadjuvant Docetaxel Clinical response High-
throughput 
RT-PCR
Supervised 85 genes 90.9% 73.3% 80.7%
Gianni 
et al. [70]
89 discovery 
92 validation
Neoadjuvant TA pCR qRT-PCR/
DNA 
microarray
Supervised 86 genes - - -
Hess et al. 
[92]
82 discovery 
51 validation
Neoadjuvant T/FAC pCR cDNA 
microarray
Supervised 30 genes 96% 52% 76%
Thuerigen 
et al. [93]
52 discovery 
48 validation
Neoadjuvant G-ET pCR cDNA 
microarray
Supervised 512 genes 95% 64% 88%
Farmer 
et al. [103]
63 Neoadjuvant FEC pCR cDNA 
microarray
Metagene 
approach
Stromal 
metagene
81% 57% 65%
aNumber of cases in discovery and validation sets. FEC, fl  uorouracil, epirubicin, and cyclophosphamide; G-ET, gemcitabine, epirubicin, and docetaxel; NPV, negative 
predictive value; pCR, pathological complete response to neoadjuvant chemotherapy; PPV, positive predictive value; qRT-PCR, quantitative reverse transcriptase-
polymerase chain reaction; RT-PCR, reverse transcriptase-polymerase chain reaction; TA, taxanes and anthracycline (that is, paclitaxel and doxorubicin); T/FAC, 
paclitaxel/fl  uorouracil, doxorubicin, and cyclophosphamide.
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To date, only a few gene signatures have been developed 
to predict the response to speciﬁ  c targeted therapies in 
breast cancer. Recently, Loi and colleagues [114] reported 
promising results focusing on PIK3CA  (phospho inosi tide-
3-kinase, catalytic) gene mutations and the PI3K-AKT-
mTOR signaling pathway targeted by PI3K/mTOR 
(mammalian target of rapamycin) inhibi  tors. By analysis 
of gene expression from 1,800 breast cancers, a gene 
expression signature associated with PIK3CA mutation 
was developed (PIK3CA-GS). Th  e signature predicted 
PIK3CA mutations in two independent datasets of breast 
cancers and was shown to identify good-prognosis 
patients in the ER-positive, HER2-negative breast cancer 
subgroup even in the case of highly proliferative tumors. 
Th   e PIK3CA-GS was nega  tively correlated with mTORC1 
signaling, making it a potential predictor of response to 
PI3K/mTOR inhibitors like rapamycin, rapamycin 
analogs, or dual kinase inhibitors. Breast cancer cell lines 
with high PIK3CA-GS were conﬁ  rmed to be resistant to 
rapamycin [114]. Th   is approach exempliﬁ  es the potential 
use of microarrays as potential predictive markers for 
tailored therapies.
Conclusions
Microarray-based gene expression proﬁ  ling analysis has 
undoubtedly had a dramatic impact on our understanding 
of breast cancer biology by bringing the concept of the 
heterogeneity of breast cancer to the forefront of breast 
cancer research and clinical practice. In fact, it is 
currently inconceivable to consider ER-positive and ER-
negative breast cancers to be a single disease. However, 
how the information derived from the classiﬁ  cation of 
breast cancer into the current molecular subtypes [17] 
will be used for breast cancer patient management 
remains unclear. First-generation prognostic signatures 
have led to the realization of the importance of 
proliferation for the prognostication of patients with ER-
positive cancers [1-3]. However, despite the resources 
allocated to their development and valida  tion, prognostic 
signatures have proven to add limited information to 
prognostic models based on clinico  patho  logical para-
meters and standardized assessment of ER, PR, HER2, 
and proliferation. Gene signatures predictive of response 
to speciﬁ  c chemotherapy regimens have proven elusive. 
With the development of massively parallel sequencing 
techno  logies, it has become possible to determine the 
repertoire of genetic aberrations a tumor harbors in a 
single experi  ment. Given the successful use of genetic 
information as predictive markers for the use of targeted 
therapies in breast cancer (for example, HER2 
ampliﬁ   cation as a predictive marker for anti-HER2 
agents) and tumors from other sites (for example, KIT 
and  PDGFRA  [platelet-derived growth factor receptor 
alpha] mutations as predictive markers of response to 
imatinib mesylate in gastrointestinal stromal tumors; 
EML4-ALK gene re  arrange  ments as predictive markers 
of ALK inhibitors in non-small cell lung cancer), it is 
plausible that the next generation of classiﬁ  ers based on 
sequencing information may have a greater impact on 
our ability to successfully stratify breast cancer patients 
into predictive subgroups [115]. Integrative approaches 
combining genetic, trans  criptomic, and proteomic 
information are likely to lead to breast cancer 
classiﬁ  cation systems that better reﬂ  ect the biology of the 
disease, and are more clinically relevant [1]. Although the 
deluge of high-throughput data will most certainly be a 
formidable challenge for the breast cancer research 
community, our ability to characterize tumors at an 
unprecedented level of detail will undoubtedly lead to 
novel paradigms for stratiﬁ   ed medicine and tailored 
therapies.
Table 3. Multigene predictors of response to endocrine treatment
Authors  Signature  Number of casesa Treatment  Context  Method  Platform
Jansen et al. 
[110]
44 genes  48 training set, 
66 validation set
TAM Recurrent 
breast cancer
Top-down (response 
vs. progression)
Microarray 
(local)
Loi et al. 
[112]
Tamoxifen predictor 
(181 genes)
99 training set, 
69 validation set 
87 validation set
TAM Adjuvant 
treatment
Top-down (relapse 
vs. no relapse)
Microarray 
(Aff  ymetrix, Santa 
Clara, CA, USA)
Oh et al. 
[111]
Estrogen-regulated 
genes 
(822 genes)
Cell lines + 65 discovery set, 
60 validation set (1) 
90 validation set (2) 
250 validation set (3)
Heterogeneous 
TAM (1) 
TAM +/− NAC (2) 
Heterogeneous (3)
Adjuvant 
treatment
Bottom-up 
(estrogen induced 
gene expression 
changes in MCF-7 
cell lines)
Microarray 
(Agilent Technologies, 
Inc., Santa Clara, CA, 
USA)
Symmans et al. 
[113]
SET index 
(165 genes)
437 training set, 
225 + 298 validation set (1) 
122 validation set (2) 
208 + 133 validation set (3)
Heterogeneous 
TAM (1) 
NAC + TAM or AI (2) 
Non-treated (3)
Adjuvant 
treatment
Bottom-up (genes 
coexpressed with 
estrogen receptor)
Microarray 
(Aff  ymetrix)
aNumber of cases in training and validation sets. AI, aromatase inhibitor; NAC, neoadjuvant chemotherapy; SET, sensitivity to endocrine therapy; TAM, tamoxifen.
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